Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.52 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5629885 | 0.98 | CHRNB2 (0.52) | CHRNB2CHRNA5CHRNA4GRM5CYP11B2 | |
| SCHEMBL5629899 | 0.98 | CHRNB2 (0.52) | CHRNB2CHRNA5CHRNA4GRM5CYP11B2 | |
| SCHEMBL4074105 | 0.88 | GRM5 (0.43) | GRM5 | |
| SCHEMBL3961132 | 0.88 | GRM5 (0.43) | GRM5 | |
| SCHEMBL3961869 | 0.88 | GRM5 (0.43) | GRM5 | |
| SCHEMBL4076476 | 0.87 | GRM5 (0.40) | CHRNB2CHRNA5CHRNA4GRM5DRD2 | |
| SCHEMBL4076468 | 0.87 | GRM5 (0.40) | CHRNB2CHRNA5CHRNA4GRM5DRD2 | |
| SCHEMBL2890850 | 0.86 | DRD2 (0.47) | CHRNB2CHRNA5CHRNA4GRM5DRD2 | |
| SCHEMBL2890857 | 0.86 | DRD2 (0.47) | CHRNB2CHRNA5CHRNA4GRM5DRD2 | |
| SCHEMBL4217061 | 0.85 | GRM5 (0.44) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101437798-A | Mglur5 modulators II | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | claimed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | CHRNB2 162/4885CHRNA5 31/4885CHRNA4 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.